What to Expect from Golden Helix in 2023 

         January 2, 2023
What to Expect from Golden Helix in 2023

Happy New Year! I hope that you all were able to enjoy quality time with your loved ones over the holidays. Now that 2022 has come to a close, we would like to take the time to say thank you while looking back on a big year full of new experiences and accomplishments. 

During the pandemic, we’ve been using the virtual conference format, and it’s been a great way to stay connected with our customers and partners. In 2022, we were able to attend our first in-person conferences around the world in several years. It turns out that the personal dialog is irreplaceable. We value these events as they give us the opportunity to informally connect with customers and partners, further building relationships.  

Last Fall, we announced the upcoming release of our VSClinical AMP TSO-500 Workflow. This release provides a solution for the clinical analysis of cancer samples, taking into consideration important biomarkers such as tumor mutational burden or microsatellite stability. This topic has been covered in my eBook, Clinical Variant Analysis for Cancer. The story of this release was also featured in several webcasts. The final release will be made available to the broader market in the next few weeks.  

We were able to win numerous awards from CorporateLiveWire, InsightsSuccess, and Biotech Breakthrough as Top Biotech Solutions in the industry. In addition, we were named a Best Company to Work for in 2022 by CIO Views. This is an incredible honor that is reflective of our success as a company over the past quarter century. We are proud of the work we do, and it is with this passion that we continue to provide innovative software solutions for our customers. 

Now, looking forward, we are excited to share our ambitious vision for 2023!  

We will start 2023 strong by releasing the new version of VSClinical supporting TSO-500 for the AMP guidelines. This required us to improve our ability to process fusions and other structural variants leveraging break-end notations. As a result, we have been working to harmonize our ability to handle all types of structural variants to be processed across the entire VSClinical platform. We are excited to announce that these capabilities will be available for germline interpretations in the first half of this year.  

We are also excited about the future of our Golden Helix CancerKB, a premium annotation source that connects biomarkers with clinical outcomes. Golden Helix CancerKB is an important piece of our company’s commitment to providing our customers with the highest value clinical database possible, ensuring that they have all the information they need to make informed decisions about their treatment options.  

As the NGS market matures, the requirements for scalable deployments are increasing. We will continue to analyze the entire underlying software stack to meet the changing scalability requirements of our customers. 

Echoing the impression of conferences in 2022, we are grateful for the opportunity to meet our customers and partners at these events. We are excited to announce our presence at the following conferences in 2023: 

  • ACMG 2023 (March 2023) 
  • AMP Europe 2023 (June 2023) 
  • ESHG 2023 (June 2023) 
  • ASHG 2023 (November 2023) 
  • AMP 2023 (November 2023) 

We look forward to meeting you and your team at these events. Overall, we had another amazing year and are so grateful to all our customers for their support. Without you, we wouldn’t be where we are today. Together with our customers and partners, we are looking forward to an exciting year, 2023! 

Leave a Reply

Your email address will not be published. Required fields are marked *